PhaseBio Pharmaceuticals Net Income 2018-2021 | PHAS

PhaseBio Pharmaceuticals net income from 2018 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
PhaseBio Pharmaceuticals Annual Net Income
(Millions of US $)
2020 $-99
2019 $-39
2018 $-24
2017 $-10
PhaseBio Pharmaceuticals Quarterly Net Income
(Millions of US $)
2021-09-30 $-32
2021-06-30 $-29
2021-03-31 $-27
2020-12-31 $-30
2020-09-30 $-25
2020-06-30 $-28
2020-03-31 $-15
2019-12-31 $-11
2019-09-30 $-11
2019-06-30 $-9
2019-03-31 $-7
2018-12-31 $-5
2018-09-30 $-8
2018-06-30 $-7
2018-03-31 $-4
2017-12-31
2017-09-30 $-3
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.100B $0.000B
PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company's product consists of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor and PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension, which are in clinical stage. PhaseBio Pharmaceuticals Inc. is based in Malvern, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.808B 8.01
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $6.887B 0.00
Arcus Biosciences (RCUS) United States $3.210B 0.00
Emergent Biosolutions (EBS) United States $2.270B 8.16
Myovant Sciences (MYOV) United Kingdom $1.508B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.469B 0.00
Zymeworks (ZYME) Canada $0.850B 0.00
SQZ Biotechnologies (SQZ) United States $0.326B 0.00
Ambrx Biopharma (AMAM) United States $0.322B 0.00
Enzo Biochem (ENZ) United States $0.170B 16.71